GeoVax Labs (Nasdaq:GOVX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GOVX 주식 개요

임상 단계의 생명공학 회사인 지오백스랩(GeoVax Labs, Inc.)은 변형된 백시니아 앙카라 바이러스 유사 입자 백신 플랫폼을 사용하여 전염병 및 고형 종양 암에 대한 인체 백신과 면역 치료제를 개발하는 회사입니다.

회사 소개

GOVX 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

수익은 연간 158.66% 증가할 것으로 예상됩니다.

위험 분석

최근 3개월간 주가 변동폭 심해

수익이 1백만 달러 미만인 경우 ( $0 )

의미 있는 시가총액이 없습니다. ( $5M )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

+ 1 더 많은 위험

GeoVax Labs, Inc. 경쟁사

Finch Therapeutics Group

OTCPK:FNCH

US$2.2m

Aptevo Therapeutics

NasdaqCM:APVO

US$2.2m

Salarius Pharmaceuticals

NasdaqCM:SLRX

US$1.7m

Aptinyx

OTCPK:APTX

US$6.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 GeoVax Labs
과거 주가
현재 주가	US$2.33
52주 최고치	US$10.24
52주 최저치	US$1.09
베타	2.78
11개월 변경	24.60%
3개월 변경 사항	18.27%
1년 변경 사항	-73.89%
33년 변화	-97.05%
5년 변화	-100.00%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

Dec 27

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Nov 27

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Oct 03

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Aug 14

Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?

Feb 18

GeoVax soars on NIAID grant for COVID-19 vaccine candidate

Jan 11

주주 수익률

	GOVX	US Biotechs	US 마켓
7D	94.2%	-1.3%	0.4%
1Y	-73.9%	7.7%	22.9%

수익률 대 산업: GOVX 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: GOVX 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is GOVX's price volatile compared to industry and market?
GOVX volatility
GOVX Average Weekly Movement	24.0%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: GOVX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: GOVX 의 주간 변동성은 지난 1년 동안 14% 에서 23% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
1988	17	David Dodd	www.geovax.com

지오백스랩은 임상 단계의 생명공학 기업으로, 변형된 백시니아 앙카라 바이러스 유사 입자 백신 플랫폼을 사용하여 감염성 질환 및 고형 종양암에 대한 인체 백신과 면역 요법을 개발합니다. 코로나19, 인간 면역결핍 바이러스(HIV), 지카 바이러스, 말라리아, 에볼라, 수단, 마르부르크, 라싸 등 출혈열 바이러스에 대한 다양한 예방 백신과 HIV, 만성 B형 간염 감염, 고형암 치료 백신을 개발 중입니다. 회사는 예방적 코로나19 치료를 위해 임상 2상 시험 중인 백신 후보물질 GEO-CM04S1, 고형암 치료를 위한 새로운 특허 제품/기술인 게뎁틴, 진행성 두경부 편평세포암 치료를 위한 임상 1/2상 시험, 범코로나바이러스 백신인 GEO-CM02를 개발 중입니다.

GeoVax Labs, Inc. 기본 사항 요약

GeoVax Labs 의 수익과 매출은 시가총액과 어떻게 비교하나요?
GOVX 기본 통계
시가총액	US$4.78m
수익(TTM)	-US$27.78m
수익(TTM)	n/a

0.0x

P/S 비율

-0.2x

P/E 비율

GOVX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
GOVX 손익 계산서(TTM)
수익	US$0
수익 비용	US$22.33m
총 이익	-US$22.33m
기타 비용	US$5.45m
수익	-US$27.78m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-10.99
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

GOVX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

GOVX 주식 개요

보상

위험 분석

GeoVax Labs, Inc. 경쟁사

OTCPK:FNCH

US$2.2m

NasdaqCM:APVO

US$2.2m

NasdaqCM:SLRX

US$1.7m

OTCPK:APTX

US$6.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

GeoVax Labs Receives a Notice from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System

Recent updates

GeoVax Labs Receives a Notice from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System

New minor risk - Shareholder dilution

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GeoVax Labs Regains Compliance with Nasdaq Minimum Bid Requirement

Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster

GeoVax Announces 1 for 15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Geovax Appoints Marc Pipas as Executive Medical Director, Oncology

New major risk - Market cap size

GeoVax Labs Receives a Notice from the Nasdaq Stock Market

Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02

New major risk - Revenue and earnings growth

GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023

GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

New major risk - Financial position

GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023

GeoVax Labs, Inc. Announces Next-Generation COVID-19 Vaccine Data to Be Presented At Two Upcoming Scientific Meetings

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors

GeoVax Labs Receives Non-Compliance Notice From Nasdaq

GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors

Price target decreased to US$5.50

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)

High number of new directors

GeoVax Labs, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

Geovax Announces Appointment of Nicole Lemerond to Its Board of Directors

GeoVax: Possible Vaccine Advancements In 2 Big Indications

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

GeoVax Labs, Inc. to Report Q2, 2022 Results on Aug 03, 2022

GeoVax Labs, Inc., Annual General Meeting, Aug 03, 2022

Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.29 loss in 1Q 2021)

Insufficient new directors

GeoVax Labs, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Geovax Labs, Inc. Announces Management Appointments

GeoVax Labs, Inc. to Report Fiscal Year 2021 Results on Mar 09, 2022

GeoVax Labs, Inc. announced that it has received $9.999998 million in funding

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial for Covid-19 Vaccine Booster

GeoVax Labs, Inc. Presents Hemorrhagic Fever Vaccine Data at World Vaccine & Immunotherapy Congress

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.73 loss in 3Q 2020)

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Geovax Presents Covid-19 Vaccine Data At the European Society of Medicine (Esmed) General Assembly

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth